SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates a major announcement, with speculation around partnerships and regulatory compliance driving excitement. Many compare ZBCN's potential to early XRP, urging others to accumulate and stake tokens. The community is closely watching for news that could catalyze a significant price movement, with some even suggesting a listing on a major exchange.

ProPetro Holding Corp. is an oilfield services company that engages in the provision of hydraulic fracturing and other complementary services. It operates through the following segments: Hydraulic Fracturing, Wireline, Cementing, and All Other. The Hydraulic Fracturing segment intends to optimize hydrocarbon flow paths during the completion phase of horizontal shale wellbores. The Wireline segment includes wireline and ancillary services on new oil well completions in the Permian Basin. The Cementing segment provides isolation between fluid zones behind the casing to minimize potential damage to hydrocarbon bearing formations or the integrity of freshwater aquifers and provides structural integrity for the casing by securing it to the earth. The company was founded by Dale Redman and Jeffrey David Smith in 2005 and is headquartered in Midland, TX.

ProPetro Holding Corp

ProPetro ($PUMP) is trending as traders discuss its recent performance relative to peers and potential for buybacks to drive scarcity. Community members are actively sharing bullish sentiments, citing technical indicators and positive setups for potential moves higher. Conversations also touch on the broader oil sector dynamics and the company's strategic positioning within it.

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM is trending amid discussions about Macau's gaming revenue and its potential impact on casino stocks, with some analysts suggesting that fears of a shutdown due to a cyclone were overblown. The community is also focused on MGM's New York casino proposal receiving key support, which could affect the broader gaming landscape. Additionally, there's growing interest in the prediction market and its potential disruption to traditional casino revenues, influencing community perspectives on the industry's innovation.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express bullish sentiment and anticipate a potential CoinMarketCap (CMC) listing. The community emphasizes positivity and shared success within the $SOL and $PUMP ecosystems, with some drawing comparisons to other meme coins like $DOGE and $PEPE. Discussions also revolve around the strength and unity of the WAGMI community.

YETI Holdings, Inc. engages in the design, marketing, and distribution of products for the outdoor and recreation market. Its products include coolers, drinkware, travel bags, backpacks, multipurpose buckets, outdoor chairs, blankets, dog bowls, apparel, and accessories. The company was founded by Roy J. Seiders and Ryan R. Seiders in 2006 and is headquartered in Austin, TX.

YETI Holdings Inc

YETI is trending amid discussions about unusual options activity, analyst ratings updates, and overall market sentiment. The community is debating the company's financial health, brand strength, and potential growth opportunities, with some highlighting concerns about tariffs and consumer spending habits. Takeover speculation and potential expansion into new markets, like military or firefighting equipment, are also circulating.

Las Vegas Sands Corp. engages in the development of destination properties. It operates through the Macao and Singapore geographical segments. The Macao segment handles the operations of The Venetian Macao, The Londoner Macao, The Parisian Macao, The Plaza Macao and Four Seasons Macao, and Sands Macao. The Singapore segment includes the Marina Bay Sands. The company was founded by Sheldon Gary Adelson in August 2004 and is headquartered in Las Vegas, NV.

Las Vegas Sands Corp

Las Vegas Sands is trending as analysts debate the impact of Macau's recovery and construction disruptions on upcoming earnings. Mixed sentiment surrounds the stock as some see an attractive entry point, while others express concern over market share and future growth prospects. The community is closely monitoring revenue data and potential stimulus impacts from China.

Melco Resorts & Entertainment Ltd. engages in the management and development of casino gaming and entertainment resort facilities. The firm focuses on the administration of Mocha Clubs, Altira Macau, City of Dreams, Studio City, and City of Dreams Manila. It operates through the following geographical segments: Macau, the Philippines, Cyprus, and Corporate and Other. The company was founded by Yau Lung Ho in December 2004 and is headquartered in Hong Kong.

Melco Resorts & Entertainment Ltd - ADR

Melco Crown Entertainment Ltd.

Melco Resorts is trending as investors assess the impact of Macau's recovery and easing travel restrictions, with the community actively discussing Golden Week data and potential catalysts like the reopening of properties and expansion into Sri Lanka. Community members are weighing positive GGR updates against concerns around the company's debt and exposure to geopolitical risks. Bullish sentiment is building around Macau's potential to return to pre-pandemic levels, with some eyeing catalysts related to visitation and GGR.

Pump.fun

Pump.fun is trending amidst community discussions around meme coins on the Solana blockchain and potential for quick gains. Conversations highlight the "WAGMI" (We're All Gonna Make It) mentality, alongside some skepticism. The community is focused on identifying the next big meme coin and the potential for high rewards.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amid discussions about the future of quantum computing and comparisons to other companies in the sector like $IONQ and $QBTS. Community members are debating the company's valuation, potential government support, and its current commercial viability. Some are pointing to a recent private placement as a sign of institutional interest, while others express skepticism about the company's fundamentals.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK is trending as community members rally around its narrative of disrupting traditional retirement plans. The project's active community and steady growth are key talking points, with many expressing bullish sentiment and anticipating further gains. As the ticker gains traction, discussions revolve around its potential to outperform traditional 401(k)s.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apellis Pharmaceuticals is drawing renewed attention from short sellers even as its stock extends a rebound sparked by better-than-expected&nbsp;bottom-line results.Short interest as a percentage of free float rose to 21.1% last week, the highest in three weeks, after bottoming near 21% in late July, according to Ortex data compiled by The Fly.&nbsp;Days-to-cover climbed to 2.8 from 2.6, although volumes stayed heavy following the earnings release, limiting further upside pressure.Shares gained 13.5% in the five sessions through Thursday and have now rallied 45% since July 31, when Apellis reported a second-quarter loss of $0.33 per share, narrower than&nbsp;analysts’ expectations.&nbsp;<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> rose 0.5% on Friday to close at $27.75, its highest level in six months, extending a four-session winning streak.Revenue of $178.5 million missed consensus by about $10 million, but investors cheered the earnings surprise along with regulatory and business updates.&nbsp;Quarterly sales were driven by $151 million from Syfovre, its treatment for geographic atrophy, and $21 million from Empaveli for paroxysmal nocturnal hemoglobinuria. Apellis also secured FDA approval of Empaveli for rare kidney diseases C3G and primary IC-MPGN, the first approved therapies for these conditions.Additionally, Apellis signed a capped royalty deal with Sobi worth up to $300 million for ex-U.S. Aspaveli sales and ended June with $370 million in cash.&nbsp;The company said the combination of cash, the Sobi payment, and future revenues should be sufficient to fund operations to profitability.Following the quarterly results, Goldman Sachs&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-buzz-surges-for-apellis-as-goldman-hikes-price-target-after-solid-syfovre-sales-fda-win-for-kidney-drug/chr3ZbiRdGS">raised its price target</a> to $26 from $24, citing strong quarterly execution and long-term potential across its complement-focused pipeline.&nbsp;Citi lifted its target to $46 from $41, calling Empaveli “best-in-class,” while Scotiabank raised its target to $22 on confidence in launch execution. Baird, BofA, and Morgan Stanley also issued upward revisions earlier in August, reflecting improving sentiment.Despite the rebound, the pickup in short positioning suggests some investors expect profit-taking after the momentum-driven surge.On Stocktwits, retail sentiment for Apellis&nbsp;remained ‘bearish’ amid ‘extremely low’ message volume.Apellis’ stock has declined 13% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

APLS stock has declined 13% so far in 2025. (Photo credit: Getty Images)

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary

Apellis stock has surged since its earnings, but rising short interest suggests some investors are betting on profit-taking.

Equity

Retail chatter around Apellis Pharmaceuticals spiked Thursday after Goldman Sachs raised its price target to $26 from $24, citing strong quarterly performance and long-term growth potential through its pipeline of immune system therapies.Goldman’s move came on the heels of Apellis’ second-quarter earnings report, which showed total revenue of $178 million.&nbsp;Syfovre, the company’s treatment for geographic atrophy,&nbsp;generated $151 million in U.S. net product sales,&nbsp;representing a 6% quarter-over-quarter&nbsp;increase in injection volume. Despite a $13 million revenue impact due to increased free sample usage linked to co-pay assistance constraints, the product maintained a dominant market position with over 60% share of new GA patient starts.&nbsp;Empaveli contributed $20.8 million in sales, supported by high compliance rates.The FDA’s recent approval of Empaveli for patients aged 12 and older with C3G and IC-MPGN added another major catalyst. Backed by Phase 3 Valiant trial data, the decision cleared the way for Empaveli’s use in two rare kidney diseases that impact approximately 5,000 patients in the U.S.&nbsp;The trial showed a 68% drop in urinary protein levels, steady kidney function, and clearance of C3 deposits, which are key indicators of kidney health. The label also includes patients with post-transplant recurrence of C3G.Analyst sentiment has improved notably in recent weeks. Citi raised its price target to $46 from $41, calling Empaveli “best-in-class” and a potential growth driver. Scotiabank lifted its target to $22, highlighting confidence in the company’s ability to execute on the Empaveli launch. Baird, BofA, and Morgan Stanley also issued upward revisions earlier this month.Apellis also strengthened its balance sheet through a $300 million royalty agreement with Sobi, selling 90% of future ex-U.S. royalties on Aspaveli, the ex-U.S. brand of Empaveli, for $275 million upfront.&nbsp;The deal includes a $25 million milestone tied to potential EMA approval for the new kidney indications later this year.On Stocktwits, retail sentiment was ‘extremely bullish’ late Thursday amid a 72% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> has declined 32.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Apellis Pharmaceuticals (APLS) spiked Thursday after Goldman Sachs raised its price target to $26 from $24. (Photo credit: Getty Images)

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug

Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from co-pay assistance constraints.

Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Repligen (RGEN) Lags Q2 Earnings Estimates

Repligen (RGEN) delivered earnings and revenue surprises of -7.50% and +3.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Retail buzz around Apellis Pharmaceuticals&nbsp;intensified on Monday after the FDA approved Empaveli,&nbsp;clearing the way for its use in treating two rare kidney diseases that often lead to kidney failure.&nbsp;The drug is now approved for patients 12 and older with C3G and IC-MPGN, which are conditions that affect 5,000 people in the U.S.&nbsp;The decision was backed by data from the Phase 3 Valiant trial, where patients on Empaveli saw a 68% drop in protein levels in their urine, a key sign of kidney stress, along with steady kidney function and signs that harmful C3 deposits were being cleared.&nbsp;The label also includes patients with post-transplant recurrence of C3G.The FDA decision comes amid a flurry of Wall Street updates on Apellis. Earlier this month, Baird raised its price target on Apellis to $50 from $47, updating its model ahead of second-quarter earnings and noting competitive developments in the C3G space.Morgan Stanley and BofA also raised their price targets, now at $26 and $24, respectively.&nbsp;BofA maintained a ‘Neutral’ rating and noted that Apellis has not provided sales guidance for Syfovre, its treatment for geographic atrophy. Morgan Stanley maintained an ‘Equal Weight’ rating and cited the royalty purchase agreement with Sobi.Apellis recently struck a $300 million royalty deal with Sobi, selling 90% of its future ex-U.S. royalties from Aspaveli, its treatment for a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), to strengthen its cash position.Apellis will receive $275 million upfront and may earn another $25 million if Aspaveli is approved for C3G and IC-MPGN in Europe.On Stocktwits, retail sentiment for Apellis was ‘extremely bullish’ amid a 2,350% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> has declined 43.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chronic kidney disease, computer illustration and light micrograph. The illustration shows the gross anatomy of kidneys with chronic glomerulonephritis. | Image source: Getty Images

Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals 

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

APLS
Apellis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest APLS News

APLS Apellis Pharmaceuticals Inc